MRUS Merus NV: רווח נקי למניה ב-12 החודשים האחרונים

The reliability of Merus N.V. (MRUS) is guaranteed by the diversification of its bispecific antibody developments, as confirmed by this GURU.Markets chart of relative EPS YoY TTM changes, where the current figure is -36.00. The business model relies on outsourcing production and testing to minimize costs. The absence of commercial revenue leaves the company dependent on grants and partnerships until the completion of clinical phases.

To identify the sector's fundamental leaders, the analyst evaluates the efficiency of profit capitalization through net income per share dynamics. This metric measures the percentage change in EPS over the last four quarters, allowing for a correlation between the costs incurred by Merus N.V. (MRUS) for expensive bispecific antibody development and FDA approval processes and the final yield, assessing business sustainability via the annual EPS TTM growth rate.